Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $104,565,563 | $86,173,723 | $68,115,246 | $56,926,636 |
| - Cash | $1,140,000 | $904,000 | $1,361,000 | $1,045,000 |
| + Debt | $16,735,000 | $20,485,000 | $9,100,000 | $10,906,000 |
| Enterprise Value | $120,160,563 | $105,754,723 | $75,854,246 | $66,787,636 |
| Revenue | $26,027,000 | $22,123,000 | $18,790,000 | $15,529,000 |
| % Growth | 17.6% | 17.7% | 21% | – |
| Gross Profit | $20,242,000 | $17,128,000 | $14,014,000 | $12,045,000 |
| % Margin | 77.8% | 77.4% | 74.6% | 77.6% |
| EBITDA | $9,304,000 | $7,234,000 | $6,051,000 | $5,720,000 |
| % Margin | 35.7% | 32.7% | 32.2% | 36.8% |
| Net Income | $3,885,000 | $2,409,000 | $2,638,000 | $2,679,000 |
| % Margin | 14.9% | 10.9% | 14% | 17.3% |
| EPS Diluted | 11.24 | 7.39 | 8.44 | 8.62 |
| % Growth | 52.1% | -12.4% | -2.1% | – |
| Operating Cash Flow | $7,388,000 | $4,470,000 | $4,665,000 | $5,470,000 |
| Capital Expenditures | -$3,005,000 | -$4,943,000 | -$1,477,000 | -$370,000 |
| Free Cash Flow | $4,383,000 | -$473,000 | $3,188,000 | $5,100,000 |